Market Overview

UPDATE: Jefferies Raises PT on Bristol-Myers Squibb on Positive Outlook

Related BMY
Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments
Pharma ETFs in Focus on String of Earnings Beat - ETF News And Commentary
The Stocks Already in Correction Mode (Fox Business)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Bristol-Myers Squibb Co. (NYSE: BMY), and raised the price target from $41.00 to $45.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Bristol-Myers Squibb Co. closed on Tuesday at $40.83.

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (BMY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional